Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002
ReutersFeb 11, 2026 12:46 PM
Feb 11 (Reuters) - Stoke Therapeutics Inc STOK.O:
STOKE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF STK-002, A POTENTIAL DISEASE-MODIFYING MEDICINE FOR THE TREATMENT OF AUTOSOMAL DOMINANT OPTIC ATROPHY (ADOA)
STOKE THERAPEUTICS INC: DOSE ESCALATION OF FIRST FOUR COHORTS WILL CONTINUE THROUGH 2026 AND EARLY 2027, PENDING SAFETY AND TOLERABILITY ASSESSMENTS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Best AI Tools for Stock Analysis in 2026 to Boost Your Investment Portfolio
As Artificial Intelligence (AI) continues to enhance everyday decision-making, these tools will allow us to leverage artificial intelligence to analyse stocks and optimise our investment portfolio.TradingKey
6 hours ago
Silver Faces Sixth Consecutive Year of Supply Deficit, How Much Upside Is Left in 2026?
TradingKey - According to the 2026 Silver Market Outlook recently released by the Silver Institute, the current robust performance of the silver market remains supported by solid fundamentals. The report indicates that the global silver market is expected to face a structural supply-demand imbalanceTradingKey
11 hours ago
Retail Trading Hub Robinhood Sinks Again, Slumping Over 7% After Hours, Signaling Lack of Interest in Crypto?
TradingKey - Robinhood (HOOD) reported a 34% decline in fourth-quarter net profit to $605 million, with total revenue of $1.28 billion missing Wall Street expectations.TradingKey
12 hours ago
After $20B Debt Sale, Google’s Rare 100-Year Bond Sparks Scrutiny: Has AI Drained the Tech Giant’s Coffers?
TradingKey - According to a Financial Times report, Google parent Alphabet (GOOG)(GOOGL) is planning to issue bonds denominated in British pounds and Swiss francs, which may include the first 100-year GBP bond of this century.TradingKey
Tue, Feb 10
U.S. January Nonfarm Payrolls Preview: Likely to Beat Expectations, but with Limited Impact on US Stocks
TradingKey - Against the backdrop of the U.S. economy demonstrating robust resilience and the coordinated easing of monetary and fiscal policies, the nonfarm payrolls data are likely to beat the market consensus expectations.TradingKey
Mon, Feb 9
